Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

被引：22

作者：

Qualls, David A.

Lambert, Nicholas ^{[1
,2
]}

Caimi, Paolo F. ^{[3
]}

Merrill, Mwanasha ^{[4
]}

Pullarkat, Priyanka ^{[5
]}

Godby, Richard C. ^{[6
]}

Bond, David A. ^{[6
]}

Wehmeyer, Graham T. ^{[9
,10
]}

Romancik, Jason ^{[11
]}

Amoozgar, Behzad ^{[12
]}

Leslie, Lori ^{[11
]}

Nastoupil, Loretta J. ^{[1
,13
,14
]}

Crombie, Jennifer L. ^{[4
]}

Abramson, Jeremy S. ^{[4
]}

Khurana, Arushi ^{[6
]}

Nowakowski, Grzegorz S. ^{[5
]}

Maddocks, Kami ^{[7
,8
]}

Rutherford, Sarah C. ^{[9
,10
]}

Kahl, Brad ^{[12
]}

Okwali, Michelle ^{[1
]}

Buege, Michael J. ^{[1
]}

Seshan, Venkatraman ^{[1
]}

Batlevi, Connie L. ^{[1
]}

Salles, Gilles ^{[1
,15
,16
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, Div Hematol Malignancies, New York, NY 10065 USA

[2] Baylor Coll Med, Dept Med, Houston, TX USA

[3] Cleveland Clin Fdn, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH USA

[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[5] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA USA

[6] Mayo Clin, Div Hematol & Oncol, Dept Internal Med, Rochester, MN USA

[7] Ohio State Univ, James Canc Hosp, Columbus, OH USA

[8] Ohio State Univ, Solove Res Inst, Columbus, OH USA

[9] Weill Cornell Med, Dept Med, Meyer Canc Ctr, New York, NY USA

[10] New York Presbyterian Hosp, New York, NY USA

[11] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA

[12] Washington Univ, Sch Med, Dept Med, St Louis, MO USA

[13] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Lymphoma Div, Hackensack, NJ USA

[14] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[15] Weill Cornell Med Coll, New York, NY 10065 USA

[16] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA

来源：

BLOOD | 2023年 / 142卷 / 26期

基金：

美国国家卫生研究院;

关键词：

D O I：

10.1182/blood.2023021274

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL. © 2023 The American Society of Hematology

引用

页码：2327 / 2331

页数：5

共 12 条

[1] Measures of follow-up in time-to-event studies: Why provide them and what should they be?
Betensky, Rebecca A.
[J]. CLINICAL TRIALS, 2015, 12 (04) : 403 - 408
[2] Speed bumps on the road to a chemotherapy-free world for lymphoma patients
Cheson, Bruce D.
[J]. BLOOD, 2016, 128 (03) : 325 - 330
[3] Crombie JL, 2023, J CLIN ONCOL, V41
[4] The European Medicines Agency Review of Tafasitamab in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Delgado, Julio
Papadouli, Irene
Sarac, Sinan B.
Moreau, Alexandre
Hovgaard, Doris
Gisselbrecht, Christian
Enzmann, Harald
Pignatti, Francesco
[J]. HEMASPHERE, 2021, 5 (12): : E666
[5] Duell J, 2021, HAEMATOLOGICA, V106, P2417, DOI [10.3324/haematol.2020.275958, 10.3324/haematol.2021.279802]
[6] Characteristics and Clinical Outcomes of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Who Received At Least 3 Lines of Therapies
Hamadani, Mehdi
Liao, Laura
Yang, Tony
Chen, Lei
Moskowitz, Craig
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (06) : 373 - 381
[7] A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis
Jurczak, Wojciech
Zinzani, Pier Luigi
Hess, Georg
Gaidano, Gianluca
Provencio, Mariano
Nagy, Zsolt
Robak, Tadeusz
Maddocks, Kami J.
Buske, Christian
Ambarkhane, Sumeet
Brugger, Wolfram
Dirnberger-Hertweck, Maren
Tillmanns, Sascha
Weirather, Johannes
Blum, Kristie
[J]. BLOOD, 2019, 134
[8] Paillassa J, 2023, Hematol Oncol, V41 Suppl 2, P591, DOI 10.1002/hon.3164_443
[9] Advanced patient age at diagnosis of diffuse large B-cell lymphoma is associated with molecular characteristics including ABC-subtype and high expression of MYC
Paul, Ulrike
Richter, Julia
Stuhlmann-Laiesz, Christiane
Kreuz, Markus
Nagel, Inga
Horn, Heike
Staiger, Annette M.
Aukema, Sietse M.
Hummel, Michael
Ott, German
Spang, Rainer
Rosenwald, Andreas
Feller, Alfred C.
Cogliatti, Sergio
Stein, Harald
Hansmann, Martin-Leo
Moller, Peter
Szczepanowski, Monika
Burkhardt, Birgit
Pfreundschuh, Michael
Schmitz, Norbert
Loeffler, Markus
Truemper, Lorenz
Siebert, Reiner
Klapper, Wolfram
[J]. LEUKEMIA & LYMPHOMA, 2018, 59 (05) : 1213 - 1221
[10] The Genetic Landscape in Elderly DLBCL Aged > 75 Years in the Australasian Leukaemia & Lymphoma Group NHL29 Iric Trial Identifies New Targetable Mutations
Rijal, Sewa
Lim, Jun Hee
Smyth, Lillian
Coombes, Caitlin
Jain, Sanjiv
Saxena, Kartik
Trotman, Judith
Verner, Emma
Gandhi, Maher K.
Gandhi, Kaushal
Talaulikar, Dipti
[J]. BLOOD, 2020, 136

← 1 2 →